🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re excited for Pfizer Inc. #ASH2024 oral presentation today, showcasing data from Ph.3 AFFINE trial of giroctocogene fitelparvovec, a gene therapy that we co-developed with and licensed to PFE for the treatment of adults w/moderately severe to severe Hem A. bit.ly/3VuMFSQ

ICYMI Pfizer Inc. unveiled detailed Ph3 AFFINE trial results at #ASH2024 for the treatment of adults with Hem A. These findings highlight the tolerability of giroctocogene fitelparvovec and its superior bleed protection compared to FVIII prophylaxis. bit.ly/4g6pqqv

Today we announce another important capsid delivery license agreement with Astellas Pharma US to deliver genomic medicines for neurological diseases. Learn more here: bit.ly/4fm9uPS

Happy Holidays from all of us at Sangamo! Dedication and passion fuel our mission to bring hope and innovation to those who need it most. Warm wishes for a joyful holiday season and a new year filled with health, happiness, and exciting possibilities!

We’re pleased to report updated data from our Ph 1/2 study in #Fabry Disease showing sustained benefit, improvements in kidney function and a favorable safety profile. Data will be shared at #WORLDSymposia on Feb. 6 at 9:30am PDT. bit.ly/42PCMUx

Our CEO, Sandy Macrae, will participate in a fireside chat @ Barclays 27th Annual Global Healthcare Conf. to discuss the continued advances in our Fabry disease program, our wholly owned neurology programs, capsid delivery technology and next-gen genome engineering capabilities.

Our fourth quarter and full year 2024 financial results will be announced on Monday, March 17, 2025, with a conference call at 4:30 PM ET. Details on how to join our conference call and webcast: bit.ly/3qc7SyU

Today, we announce our fourth quarter and full year 2024 financial results, highlighting the progress made throughout the year. Learn more here: bit.ly/42bANsD

Today we announce our third capsid license agreement. We are proud to collaborate with Eli Lilly and Company to deliver genomic medicines for diseases of the central nervous system. Learn more here: bit.ly/4crP2x5

This #FabryAwarenessMonth, we stand with this community - patients, families, and advocates - united in our commitment to advancing potential treatment options. Together, through innovation, we’re working toward a future with better outcomes for all living with Fabry disease. 💙

We’re proud to share that all our abstracts were accepted to #ASGCT2025 —including three oral presentations, with our prion data selected for the prestigious #PresidentialSymposium. Click here to learn more: bit.ly/4jQF4ro #ASGCT #genomicmedicine #neurology #Innovation

Today, we announce progress in our Fabry disease program, achieving important derisking milestones in our pathway to anticipated BLA submission. Learn more: bit.ly/4jBVa8I

Our first quarter 2025 financial results will be announced on Monday, May 12, 2025, with a conference call at 4:30 PM ET. Details on how to join: bit.ly/44rR52m

We’re truly honored to be showcasing our exciting science in the prestigious Presidential Symposium—one of the most selective and high-profile sessions @ASGCT.

Our first quarter 2025 financial results will be announced on Monday, May 12, 2025, with a conference call at 6:30 PM ET – postponed from the original time of 4:30 PM ET. Details on how to join: bit.ly/4kddo07

Today, we announce our first quarter 2025 financial results, highlighting the progress made this quarter. Learn more here: bit.ly/44Bdv1g

🔬 ICYMI: Exciting progress was highlighted last week during the prestigious #PresidentialSymposium at #ASGCT2025, showcasing promising data for the potential treatment of prion disease. To view this presentation and more Sangamo content from ASGCT, bit.ly/4dBMflx

Join our CEO, Sandy Macrae, for a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4that 7:35 a.m. EDT. For the latest information, visit our website: bit.ly/3sfJt2f

Join our CEO, Sandy Macrae, for a fireside chat at the H.C. Wainright 6th Annual Neuro Perspectives Hybrid Conference on Tuesday, June 17th at 7:00 a.m. EDT. For the latest information, visit our website: bit.ly/3sfJt2f #GenomicMedicine #Neurology

Today we are excited to share positive topline results for our registrational STAAR study in Fabry Disease. Learn more here: bit.ly/4ehdfqX